2006 Annual Meeting | Clinical Approach to Muscle Disease

Date Sunday 04/02/06

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Matthew P. Wicklund, MD, FAAN

Topic(s)

Learning Objectives Upon Completion:
Participants should become familiar with the evaluation and treatment of acquired and genetic disorders of muscle, including basic, unusual, and novel diseases; broaden their differential diagnoses; and better understand recent diagnostic and therapeutic advances.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Resident

Event Timeline
09:00 AM - 09:50 AM		Myopathy Made Ridiculously Simple: A Pattern Recognition Approach Carlayne E. Jackson, MD, FAAN
09:50 AM - 10:40 AM		The Limb-Girdle Muscular Dystrophies: Ever-Expanding Boundaries Matthew P. Wicklund, MD, FAAN
10:40 AM - 11:00 AM		Break
11:00 AM - 11:45 AM		The Inflammatory Myopathies Alan Pestronk, MD, FAAN
11:45 AM - 12:30 PM		A Phenotypic Approach to Unusual Myopathic Disorders Patrick M. Grogan, MD, FAAN
12:30 PM - 12:45 PM		Questions and Answers and Special Cases

Faculty Disclosures
Matthew P. Wicklund, MD, FAAN	Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus Therapeutics. Dr. Wicklund has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta Therapeutics. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Spark Therapeutics. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ultragenyx. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex Pharmaceuticals. The institution of Dr. Wicklund has received research support from Orphazyme. The institution of Dr. Wicklund has received research support from Muscular Dystrophy Association. The institution of Dr. Wicklund has received research support from Coalition to Cure Calpain 3. The institution of Dr. Wicklund has received research support from Sarepta Therapeutics. The institution of Dr. Wicklund has received research support from ML Bio. The institution of Dr. Wicklund has received research support from Alexion. The institution of Dr. Wicklund has received research support from Acceleron. The institution of Dr. Wicklund has received research support from Edgewise. The institution of Dr. Wicklund has received research support from Fulcrum. The institution of Dr. Wicklund has received research support from Roche-Genentech. The institution of Dr. Wicklund has received research support from Avidity. Dr. Wicklund has received research support from Harmony Bioscience.
Carlayne E. Jackson, MD, FAAN	Dr. Jackson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe Pharma America. Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for AAN. The institution of Dr. Jackson has received research support from NIH. The institution of Dr. Jackson has received research support from Massachussetts General Hospital.
Patrick M. Grogan, MD, FAAN	No disclosure on file
Alan Pestronk, MD, FAAN	The institution of Dr. Pestronk has received research support from Jain. The institution of Dr. Pestronk has received research support from Fulcrum. The institution of Dr. Pestronk has received research support from Argenyx. The institution of Dr. Pestronk has received research support from NeuroNext.

��ɫ��

��ɫ��